發送短信 : Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

  _  __   _    _     _____    _    _    ______   
 | |/ // | || | ||  /  ___|| | || | || |      \\ 
 | ' //  | || | || | // __   | || | || |  --  // 
 | . \\  | \\_/ || | \\_\ || | \\_/ || |  --  \\ 
 |_|\_\\  \____//   \____//   \____//  |______// 
 `-` --`   `---`     `---`     `---`   `------`